Defunct Company
Total Trials
2
As Lead Sponsor
1
As Collaborator
Total Enrollment
96
NCT02100839
Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 31, 2014
Completion: Dec 31, 2014
NCT05718323
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Phase: Phase 2
Role: Collaborator
Start: Dec 20, 2023
Completion: Jun 30, 2026